Navigation Links
BioMS Medical Announces Third Quarter 2009 Results
Date:11/12/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 12 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS) today announced financial and operational results for the three and nine months ended September 30, 2009.

During the quarter, the exclusive license and collaboration agreement between BioMS Medical and Eli Lilly and Company (NYSE: LLY) for dirucotide was terminated with the effect that all commercial rights to dirucotide are returned to BioMS.

"During the third quarter, the Company made significant progress towards completing its termination of the dirucotide clinical trials, and in reducing expenditures," said Kevin Giese, President and CEO of BioMS Medical. "We anticipate that this process of ending the trials, which includes the collecting, and review and analysis of the trial data, should be substantially completed by the end of the year."

Financial Results

The consolidated net income of the Corporation for the three months ended September 30, 2009 was $9.9 million or $0.11 per share compared with consolidated net income of $6.3 million or $0.07 per share for the previous year. The consolidated net income of the Corporation for the nine months ended September 30, 2009 was $10.1 million or $0.11 per share compared with a consolidated net loss of ($0.8) million or ($0.01) per share for the same period in 2008.

Revenue earned from the collaboration agreement in the amount of $20.6 million for the three months and $45.6 million for the nine months ended September 30, 2009 compared to $16.1 million and $40.1 million for the three and nine months ended September 30, 2008. The revenue represents the amortization of deferred revenue from the US$87 million upfront licensing fee payment and the US$10 million development milestone payment received from Lilly from the Agreement that was terminated on September 2, 2009. Deferred revenue is recorded as revenue as the Corporation incurred the co
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. BioMS Medical announces second quarter 2009 results
2. BioMS Medical to present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences
3. BioMS Medical to participate in panel session at Bio International Convention 2009
4. BioMS Medical Announces First quarter 2009 results
5. BioMS Medical to present at Alberta Economic Forum in Geneva
6. BioMS Medical to present at BioFinance 2009
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical Announces 2008 Year End Results
10. BioMS Medical warrant extension
11. BioMS Medical to present at BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... ... 26, 2015 , ... MediVet Biologics, a leader in Veterinary ... to open in Manhattan, Kansas in early October, 2015. The location of the ... and development through collaboration with researchers from Kansas State University’s College of Veterinary ...
(Date:8/26/2015)... , ... August 26, 2015 , ... ... increasing its investment in the development and manufacture of highly valued cardiac markers ... company’s scientific team's extensive expertise with protein chemistry has led to the development ...
(Date:8/26/2015)... , Aug. 26, 2015 Intrexon Corporation ... announced today the closing of its previously announced public ... by the underwriters of their option to purchase an ... offering price of $41.00 per share.  The exercise of ... of common stock sold by Intrexon to 5,609,756 shares ...
(Date:8/26/2015)... OXFORD, England , August 26, 2015 ... P2i Ltd against Europlasma NV relating to P2i ... parties have resolved their dispute in the United ... or liability on the part of either party. As a ... the Central District of California dismissed ...
Breaking Biology Technology:MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4P2i Settles United States Litigation 2
... Next Generation Cellulosic Feedstock Program, KINGSTON, ... Inc. (PPI) has,announced today that it has ... non-food crops for industries seeking renewable,feedstocks for ... The facility, located in Waterloo, New York, ...
... -, BRIDGEWATER, N.J. and NEW YORK, June 18 ... launch backed by Warburg Pincus, the leading global private ... GANIC from Warburg,Pincus Private Equity X, L.P., a $15 ... was founded by a highly seasoned group of senior,executives ...
... Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced that ... present at the,Jefferies & Co. 2nd Annual Healthcare Conference ... June 25, 2008., An audio webcast of Dr. ... webcast at: http://www.alexionpharm.com . An archived version of ...
Cached Biology Technology:Performance Plants Establishes U.S. Biofuels Facility 2GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives 2GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives 3
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/5/2015)... , August 5, 2015 ... & Access Management Market by Software, Services, Vertical (BFSI, Airport, ... & Geography - Global Forecast to 2020", published by ... Management Market globally into various segments. The global PIAM ... 2014 to $546.2 Million by 2019, at a CAGR ...
(Date:8/3/2015)... JOSE, Calif. , Aug. 3, 2015 ... of human interface solutions, today announced that members of ... community at the Pacific Crest Global Technology Leadership Forum ... Time. The conference will be held at the Sonnenalp ... The presentation may include forward-looking information. An ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... Scientists at the Weizmann Institute of Science recently discovered ... bones. Their findings were published in the Proceedings of ... is a potential source of information on the evolution, ... humans. But if it is not well preserved or ...
... for decades to determine the chemical composition of ... identify viruses, and never in complex environmental samples. ... School of Public Health recently demonstrated that proteomic ... for this purpose. Using a two-step process, researchers ...
... who have induced heart cells in culture to mimic ... to gain new insight into the mechanisms that spawn ... revealed that while electric shocks such as those delivered ... they cause them to accelerate and multiply. , The ...
Cached Biology News:Ancient fossil DNA found preserved in crystal 2Ancient ants arose 140-168 million years ago 2Engineered heart tissue offers insights into irregular heartbeats, defibrillator failure 2Engineered heart tissue offers insights into irregular heartbeats, defibrillator failure 3
SMVT (N-14)...
...
... is a cytidine analog that has been shown ... Immunogen: Chemical / Small Molecule conjugated ... of the ddC antiserum was determined by calculating ... moles of ddC analog at the 50% intercept ...
... Jouan MSC series of Class II ... conditions and certification to the world's ... ensures that the cabinets cannot be ... Natural lighting, low noise and arm ...
Biology Products: